For patients with refractory, recurrent, or progressive disease or intolerance to conventional HLH therapy.
(95% CI: 0.42, 0.81; P = 0.013)
Gamifant was shown to neutralize IFNγ as measured by a rapid and sustained reduction in the plasma concentrations of CXCL9, a chemokine induced almost exclusively by IFNγ.See how Gamifant works
Primary hemophagocytic lymphohistiocytosis (HLH) is a rare hyperinflammatory condition that mostly affects children, but can also occur in adults and teenagers.3,6
Gamifant reduces the inflammatory symptoms of primary HLH by neutralizing IFNγ.1
Gamifant is given as an intravenous infusion twice a week until hematopoietic stem cell transplantation (HSCT) is performed.1
Gamifant can be ordered through our specialty pharmacy or one of our specialty distributors.